[posting]59562395[/posting]--> ist ja nichts Neues, daß Studiendaten (bis zur Zulassung einschließlich) im Biotech-Bereich nicht den ursprünglichen Versprechungen bzgl. ihrer Wirksamkeit entsprechen:
24.12.2018
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
https://www.businesswire.com/news/home/20181224005136/en/INV…
=>
...The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin\u2122 gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).”
An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day....
--> Seeking Alpha: https://seekingalpha.com/news/3413862-investors-underwhelmed…
=> wie gewonnen, so zerronnen:
=> ist nur eine Frage der Zeit, bis auch die blaue Linie zurück auf den NBI fällt
